Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-Negative PR-Negative HER2-Negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01624441
What this trial is testing

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 40
Large-scale testing (Phase 3)Study completedNCT02032277
What this trial is testing

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
AbbVie 634
Testing effectiveness (Phase 2)Study completedNCT03254654
What this trial is testing

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Who this might be right for
Advanced Triple-Negative Breast Cancer
Fudan University 66
Testing effectiveness (Phase 2)Ended earlyNCT00817531
What this trial is testing

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Who this might be right for
Breast Cancer
Baylor Breast Care Center 22
Testing effectiveness (Phase 2)UnknownNCT04745975
What this trial is testing

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Fudan University 100
Not applicableLooking for participantsNCT05396612
What this trial is testing

Role of the Immune Environment in Response to Therapy in Breast Cancer

Who this might be right for
Breast CancerER Positive Breast CancerHER2-negative Breast Cancer+1 more
Abramson Cancer Center at Penn Medicine 300
Testing effectiveness (Phase 2)Study completedNCT02807844
What this trial is testing

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Who this might be right for
Triple Negative Breast CancerPancreatic CarcinomaMelanoma+1 more
Novartis Pharmaceuticals 141
Testing effectiveness (Phase 2)UnknownNCT03805399
What this trial is testing

FUSCC Refractory TNBC Umbrella (FUTURE)

Who this might be right for
Triple-negative Breast Cancer
Fudan University 140
Early research (Phase 1)Ended earlyNCT02543645
What this trial is testing

Varlilumab and Atezolizumab in Patients With Advanced Cancer

Who this might be right for
Carcinoma, Renal CellKidney DiseasesKidney Neoplasms+11 more
Celldex Therapeutics 18
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Testing effectiveness (Phase 2)Looking for participantsNCT07108309
What this trial is testing

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Biocad 124
Testing effectiveness (Phase 2)Ended earlyNCT02347163
What this trial is testing

Pre-operative Zoledronate in Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Mario Negri Institute for Pharmacological Research 22
Testing effectiveness (Phase 2)Ended earlyNCT04424641
What this trial is testing

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumor(s)Prostate CancerEsophageal Cancer+5 more
Genmab 48
Testing effectiveness (Phase 2)Looking for participantsNCT07104266
What this trial is testing

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Who this might be right for
Triple-Negative Breast Cancer
Université de Sherbrooke 30
Testing effectiveness (Phase 2)Ended earlyNCT02993094
What this trial is testing

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Arbeitsgemeinschaft medikamentoese Tumortherapie 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06371807
What this trial is testing

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab

Who this might be right for
Early Breast CancerTriple Negative Breast Cancer
Fundacao Champalimaud 20
Large-scale testing (Phase 3)Study completedNCT02926196
What this trial is testing

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Who this might be right for
Triple Negative Breast Neoplasms
Istituto Oncologico Veneto IRCCS 474
Testing effectiveness (Phase 2)Looking for participantsNCT07011654
What this trial is testing

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Who this might be right for
Metastatic Triple-Negative Breast Cancer
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT00371254
What this trial is testing

Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Next Page